LAURA STEVENS: Open Payments
NPI 1457815235 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,827 in 149 payments from 22 companies in 2025. Trend: 2023 $2,889 · 2024 $2,950 · 2025 $2,827
Food & beverage: $2,827
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 31 | $717 |
| GlaxoSmithKline, LLC. | 26 | $308 |
| United Therapeutics Corporation | 12 | $258 |
| Grifols USA, LLC | 10 | $232 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $182 |
| GENZYME CORPORATION | 9 | $166 |
| Verona Pharma, Inc. | 9 | $166 |
| Merck Sharp & Dohme LLC | 7 | $165 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
Products named: DUPIXENT, TEZSPIRE, Tyvaso, FASENRA, Prolastin-C Liquid, TRELEGY ELLIPTA, Ohtuvayre, NUCALA.
Industry payments across MS — which companies pay providers there.
